Sequiam Biometrics (fka SQUM)

[jack of stocks]

Unfortunately if Crestview had not become involved, Biometric Investors as funded by the previous investor would have continued funding Sequiam with the only exception whereas Nick VandenBreckel would have to resign.

Nick V still resigned but did a deal with Crestview Capital that obviously had different intentions.

Notice how Crestview Capital which now owns Biometric Investors has conducted business in the past.

Crestview SEC violation and fine

Crestview and Flink made false representations in the offering documentation for the two registered direct offerings that Crestview funds had not shorted the respective issuer's stock in the ten trading days preceding the signing of the documentation. Without admitting or denying the Commission's allegations, Crestview and Flink have agreed to a civil injunction for violations of the federal securities laws. In addition, Crestview agreed to pay $394,640 in disgorgement and civil penalties and to retain an independent consultant to monitor Crestview's compliance procedures. Also, Flink agreed to pay $120,000 in civil penalties. After filing, the Court entered final judgments against Crestview and Flink today.

The Commission's complaint, filed in the United States District Court for the Northern District of Illinois, alleges that Crestview funds agreed to invest $1.4 million in a registered direct offering by Introgen Therapeutics, Inc. (Introgen) that was publicly announced on November 26, 2003 and agreed to invest $1.25 million in a registered direct offering by Targeted Genetics Corporation (Targeted Genetics) that was publicly announced on February 2, 2004. The complaint further alleges that as a condition to participating in the offerings, Introgen and Targeted Genetics required the Crestview funds to represent in the subscription agreements for the offerings that Crestview funds had not shorted Introgen and Targeted Genetics stock respectively in the ten days preceding the execution of the agreements. The complaint alleges that Flink, who is 50 years old and resides in Deerfield, Illinois, acting with full authority for Crestview, knowingly or recklessly signed the Introgen and Targeted Genetics subscription agreements on behalf of Crestview funds even though Crestview funds had short sold 108,218 and 255,000 shares respectively of Introgen and Targeted Genetics stock in the ten days preceding the execution of the subscription agreements for each of the companies. Flink's shorting of Introgen and Targeted Genetics stock yielded Crestview funds $197,320 in illegal profits.


http://www.sec.gov/litigation/litreleases/2007/lr20017.htm